Dr. Richard Moscicki, Deputy Center Director for Science Operations at the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), noted in his remarks at the FDA public workshop on Complex Issues in Developing Drug and Biological Products for Rare Diseases held earlier this month that more than a third of the novel drugs approved in CY13 treat rare disease.
Most Recent Posts
Nelson Mandela once said, “Education is the most powerful weapon which you can use to change the world.” This statement couldn't be more accurate.
This week at the STEM Saves Lives forum, we were fortunate enough to hear from the first woman of color to go into space. Now, we hear from a woman who considered taking a similar path, but instead decided to pursue a career in biopharmaceutical research.
It’s been widely reported that the United States has a science, technology, engineering and math (STEM) education problem. As we fall behind other countries in STEM proficiencies, our leadership in innovation across sectors is at risk.
The next new addition to our “I am Research, Progress, Hope” series is a scientist from Pfizer who works in neuroscience – leading a multi-disciplinary team focusing on Alzheimer’s and other serious diseases of the brain including schizophrenia.
Like a complex puzzle, the research and development (R&D) process for new medicines requires many pieces to work concurrently to ensure success. From the patients who inspire us to the experts behind the research, every part is critical to a prosperous pipeline for patients suffering from some of the world’s most debilitating diseases.
As we continue our discussion of STEM education this week, we’re providing a window into the daily lives of some of our member companies’ biopharmaceutical researchers and getting their advice for future STEM educated individuals in our “I am Research, Progress, Hope” series.
Just one week from today, PhRMA is joining with U.S. News and World Report for a forum on a very important topic: Science, math, engineering and technology education, better known as STEM education. Numerous studies have shown that the United States has a STEM problem. We are falling behind other countries, with our students ranking in the bottom half of OECD nations in both science and math literacy.
The rare disease community lost a champion last week when Sam Berns passed away at age 17 due to complications from progeria, an extremely rare genetic disease which causes accelerated aging. Last October, Sam shared his inspiring philosophy for a happy life in his talk at TEDxMidAtlantic.
Those who advocate more aggressive outreach to patients to talk about the potential benefits and importance of clinical research would certainly have felt vindicated during the roll out of "Research in Your Backyard: Pharmaceutical Clinical Trials in Iowa" yesterday in Des Moines.
This year promises to be a busy, productive one for PhRMA and our member companies, and we started the week off right by focusing on several key industry issues, including rare diseases, STEM education, and medical advances.
While 2013 was a great year, 2014 promises to be even better. As we look ahead, our focus on facilitating thoughtful discussions on some of the most important health care topics will continue.
Last week, the Administration gave a boost to NASA, vowing to keep the International Space Station in orbit until 2024, four years longer than its current approved tenure. With so many questions left unanswered and so much unchartered territory, space exploration is a lot like the search for treatments and cures.
Technology is rapidly changing how we conduct even the simplest of daily tasks, and with smartphones, tablets, and other mobile devices, being “connected” is no longer a function of sitting at a desk in front of a computer. We now carry some of the most powerful computers in the palm of our hands, and mobile platforms have opened the door to the creation of some incredibly innovative applications.
Earlier this week, Scientific American published an excellent blog post by chemist Ashutosh Jogalekar with the cheeky title, “Why drugs are expensive: It’s the science, stupid.” In his well-informed commentary, Jogalekar describe